CytoMed Signs MOU with CNK Therapeutics for Gene Grafting Technology in CAR Therapies
publication date: Aug 16, 2023
Singapore CytoMed Therapeutics signed a Memorandum of Understanding that, if finalized, would allow the company to use Hangzhou CNK Therapeutics’ PiggyBac technology. The PiggyBac technology would be used to permanently graft Chimeric Antigen Receptor (CAR) genes into gamma delta (γδ) T cells via a non-viral gene editing method. As a result, CAR gene expression is expected to continue for as long as the γδ T cells are present in the body, potentially increasing the therapeutic effect. The two companies may also form a JV to conduct clinical trials in China. More details....
Stock Symbol: (NSDQ: GDTC)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.